HPRA Drug Safety Newsletter Edition 78
Download:
hpra-drug-safety-newsletter-edition-78.pdf
217 KB
The latest edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support the safe and appropriate use of the following medicines:
Otezla (apremilast) - Important advice regarding suicidal ideation and behaviour
Lenalidomide (Revlimid) - Advice regarding viral reactivation
Levetiracetam 100mg/ml Oral Solution - Global reports of medication errors resulting in the administration of higher than intended doses of levetiracetam
Improved Access to Educational Materials on the HPRA website
Direct Healthcare Professional Communications published on the HPRA website since the last Drug Safety Newsletter
« Back